A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol. [SUBSTUDY OF 700216591]

Trial Profile

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol. [SUBSTUDY OF 700216591]

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Trastuzumab emtansine (Primary) ; Tamoxifen; Trastuzumab
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms ADAPT-HER2+HR+
  • Most Recent Events

    • 06 Jul 2017 Primary endpoint (Comparison of the pCR rates in patients with HER2+/HR+ breast cancer treated by preoperative T-DM1 with standard endocrine therapy vs trastuzumab with standard endocrine therapy) has been met as per the results published in the Journal of Clinical Oncology
    • 06 Jul 2017 Primary endpoint (Comparison of the pCR rates in patients with HER2+/HR+ breast cancer treated by preoperative T-DM1 with standard endocrine therapy vs trastuzumab with standard endocrine therapy) has not been met as per the results published in the Journal of Clinical Oncology
    • 06 Jul 2017 Primary endpoint (Comparison of the pCR rates in patients with HER2+/HR+ breast cancer treated by preoperative T-DM1 vs trastuzumab with standard endocrine therapy.) has been met as per the results published in the Journal of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top